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ABSTRACT
Background Although BRCA1 and BRCA2 mutations
account for only ∼27% of the familial aggregation of
ovarian cancer (OvC), no OvC risk prediction model
currently exists that considers the effects of BRCA1,
BRCA2 and other familial factors. Therefore, a currently
unresolved problem in clinical genetics is how to counsel
women with family history of OvC but no identiﬁable
BRCA1/2 mutations.
Methods We used data from 1548 patients with OvC
and their relatives from a population-based study, with
known BRCA1/2 mutation status, to investigate OvC
genetic susceptibility models, using segregation analysis
methods.
Results The most parsimonious model included the
effects of BRCA1/2 mutations, and the residual familial
aggregation was accounted for by a polygenic
component (SD 1.43, 95% CI 1.10 to 1.86), reﬂecting
the multiplicative effects of a large number of genes
with small contributions to the familial risk. We
estimated that 1 in 630 individuals carries a BRCA1
mutation and 1 in 195 carries a BRCA2 mutation. We
extended this model to incorporate the explicit effects of
17 common alleles that are associated with OvC risk.
Based on our models, assuming all of the susceptibility
genes could be identiﬁed we estimate that the half of
the female population at highest genetic risk will
account for 92% of all OvCs.
Conclusions The resulting model can be used to
obtain the risk of developing OvC on the basis of
BRCA1/2, explicit family history and common alleles.
This is the ﬁrst model that accounts for all OvC familial
aggregation and would be useful in the OvC genetic
counselling process.
INTRODUCTION
Ovarian cancer (OvC) is the third most common
gynaecological cancer (http://www.cancerresearchuk.
org/cancer-info/cancerstats/). It is well-established
that OvC has a signiﬁcant genetic component, with
the risk to ﬁrst-degree relatives of patients with OvC
estimated to be approximately three times greater
than the risk to women in the general population.1 2
High-penetrance mutations in BRCA1 and BRCA2
account for ∼27% of these familial cancers1 and
another 10% are accounted for by rare variants in
the MMR genes, RAD51C, RAD51D and BRIP1
(http://www.nature.com/icogs/primer/common-variation-
and-heritability-estimates-for-breast-ovarian-and-prostate-
cancers/).
Risk models that incorporate both BRCA1 and
BRCA2 mutations and other sources of variation are
required to provide accurate estimates of mutation
carrier probabilities and cancer risk for use in genetic
counselling. Existing risk-prediction models for
familial OvC such as Breast and Ovarian Analysis of
Disease Incidence and Carrrier Estimation Algorithm
(BOADICEA) or BRCAPRO3 4 assume that all famil-
ial aggregation to OvC is due to BRCA1 and BRCA2
mutations but this does not reﬂect our understanding
of OvC genetic susceptibility. As a consequence,
these models may underestimate OvC risks in
women without mutations in these genes. Therefore,
how to counsel women with family history of OvC
but without BRCA1 or BRCA2 mutations has
remained a major unresolved question in clinical
cancer genetics.
We have used data from a large, population-
based series of cases diagnosed with OvC, the
Studies of Epidemiology and Risk factors in Cancer
Heredity (SEARCH), and segregation analysis
methods to develop genetic models for OvC that
incorporate the effects of BRCA1 and BRCA2 muta-
tions and model the residual familial aggregation to
OvC. The explicit effects of 17 common OvC sus-
ceptibility alleles, identiﬁed through genome-wide
association studies (GWAS), were then incorporated
into the algorithm. We ﬁnally considered the impli-
cations of our risk prediction model for OvC risk
stratiﬁcation in the general population and its use
in OvC prevention.
MATERIALS AND METHODS
Study population
We used data on 1548 OvC cases (probands)
recruited between 1999 and 2010, along with infor-
mation on their ﬁrst-degree and second-degree rela-
tives ascertained through an epidemiological
questionnaire. The probands were drawn from
SEARCH, a large population-based study with cases
ascertained through the Eastern Cancer Registration
and Information Centre.1 5 Half-sibling status and
relative type to the proband, age at cancer diagnosis,
cancer site, vital status, status age (the age at death if
deceased, the current age if alive) and year of birth
were recorded for all probands and relatives.
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BRCA1 and BRCA2 mutation screening
SEARCH OvC probands were screened for BRCA1 and BRCA2
mutations as part of a separate project to evaluate the contribu-
tion of rare, high-risk and moderate-risk variants to overall OvC
risk in the general population.6 Brieﬂy, this involved targeted
sequence library preparation using multiplexed 48.48 Fluidigm
access arrays and sequencing on an Illumina HiScan. BRCA1
and BRCA2 mutation status information was available on all
1548 probands. The following alterations were considered
pathogenic: protein-truncating insertion/deletion variants, non-
sense mutations, consensus splice-site variants and missense var-
iants with reported damaging effect on protein function. For
the purpose of our analysis, BRCA1 and BRCA2 mutation status
were both recorded simply as mutation-positive or negative,
with no distinction between different mutation types by location
or functional effect.
Statistical analysis
Segregation analysis of OvC
Complex segregation analysis was used to ﬁt genetic models to
the occurrence of OvC in families, incorporating the explicit
effects of BRCA1 and BRCA2 mutations on OvC risk. Female
family members were followed from birth until the ﬁrst of OvC
diagnosis age, age at questionnaire, death age or age 80. We also
considered breast cancer occurrence, but individuals were con-
tinued to be followed up for OvC after a breast cancer diagnosis
in the analysis. Data on risk-reducing surgeries were not avail-
able in relatives of probands, and we were therefore unable to
censor at these events. However, since this is a population-based
study in which women with OvC diagnosis were recruited soon
after diagnosis, and participants were not aware of their muta-
tion status at the time of recruitment, we do not expect a high
prevalence of risk-reducing surgeries at the time of pedigree
collection.
To incorporate the effects of BRCA1 and BRCA2 mutations
and to take account of changes in cancer incidences over time,
the OvC incidence for a female i was assumed to depend on the
underlying genetic effects through a model of the form
liðg; t; kÞ ¼ l0ðt; kÞ expðGiðt; kÞ þMiþPiÞ;
where l0ðt; kÞ is the baseline incidence for individuals born in
birth cohort k and Giðt; kÞ is the logarithm of the relative risk
associated with BRCA1/BRCA2 mutation status g, for age t and
cohort k; Mi is the logarithm of the relative risk associated with
a third hypothetical major gene and Pi is the polygenic compo-
nent. Pi is assumed to have a normal distribution with variance
σ2 and mean zero and is approximated by the hypergeometric
distribution to make it amenable to ‘peeling’.7 8 Eight sets of
birth cohort and calendar-period-speciﬁc incidences for OvC in
the general population were derived on the basis of incidences
for England and Wales as described previously for the
BOADICEA model.9 The eight cohorts included individuals
born pre-1920 then in 10-year intervals up to post 1970. As the
number of BRCA1 and BRCA2 mutation carriers in the
SEARCH dataset was too small to obtain reliable cancer risk
estimates for mutation carriers, we also used external estimates
of the OvC and breast cancer relative risks for BRCA1 and
BRCA2 carriers relative to population incidences, based on some
of the largest studies available.10 Hence, the average BRCA1 and
BRCA2 OvC and breast cancer incidences over all possible
genetic effects in the model were ﬁxed. The cohort-speciﬁc
baseline incidences for BRCA1 and BRCA2 carriers were
obtained for each cohort separately by constraining the average
incidences over all possible genetic effects to agree with the
external estimates.8 Similarly, the baseline incidences for non-
mutation carriers were obtained by constraining the incidences
over the BRCA1, BRCA2, other major gene and polygenic
effects to agree with the population incidences (see online sup-
plementary material methods).
Since BRCA1 and BRCA2 mutations are also associated with
increased breast cancer risks,10 11 we incorporated the effect of
these mutations on breast cancer incidence. We assumed a
similar model for the breast cancer incidence; however, the
breast cancer incidence was assumed to depend on only the
effects of BRCA1 and BRCA2 mutations.
In our analyses, we considered models with just the BRCA1
and BRCA2 effects, and models that additionally included a
dominant, recessive or co-dominant hypothetical major gene
and/or a polygenic component.
All the families used in the analysis consisted of women ascer-
tained on the basis of OvC. Thus, to adjust for ascertainment
bias,12–14 we employed an ascertainment assumption-free
approach in which the likelihood of each family’s joint pheno-
type was modelled as PðyÞ=PðyiÞ, where y is the vector of all the
family phenotypes including all phenotypic and genotypic infor-
mation on the proband and yi is the phenotype of the proband.
A sensitivity parameter was introduced, giving the probability of
detecting a mutation if one existed, to take account of the fact
that mutation screening methods used cannot detect large rear-
rangements in BRCA1 and BRCA2.6 A ﬁxed value of 0.9 for
both BRCA1 and BRCA2 was used in all models, but additional
sensitivity analyses were performed.
Maximum-likelihood estimates of the gene frequencies, poly-
genic standard deviation and the log relative risk for the hypo-
thetical major gene were calculated using pedigree analysis
software MENDEL.15 SEs for each parameter were obtained
from the observed information matrix and were used to calcu-
late 95% CIs. To assess goodness of ﬁt, all of the models with a
polygenic or major gene component were compared with the
baseline model with just BRCA1 and BRCA2 effects using likeli-
hood ratio tests (LRTs). Further LRTs were used to test for dif-
ferences between the ﬁt of nested models and the Akaike
information criterion (AIC) equal to −2(log-likelihood – no. of
parameters) was used to compare non-nested models.
OvC risk, mutation frequency and carrier numbers prediction
We used each of the models ﬁtted to predict BRCA1 and BRCA2
mutation carrier frequencies and the risk of developing OvC in
the future using the methods previously described in ref [11].
The predictions were used to compare the ﬁt of the models as
part of an internal validation. Although goodness-of-ﬁt tests are
not valid using the data generating dataset, we calculated χ2
goodness-of-ﬁt tests that compared the observed and expected
number of mutations and used these as an indicator of the
model ﬁt to the data. The expected number of mutation carriers
was computed as the sum of the predicted BRCA1 and BRCA2
carrier probabilities across all SEARCH families.
We used the most parsimonious model to estimate risk of
developing OvC for a 50-year-old woman to demonstrate the
possible clinical implications for different scenarios of BRCA1
and BRCA2 carrier status and extent of family history. The
results were compared with the corresponding predictions from
the current BOADICEA model.
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Incorporating SNPs into the risk prediction algorithm
We extended the most parsimonious model to also incorporate
the explicit effects of the known common OvC susceptibility
alleles following the methodology already published in the
context of prostate cancer.16 The residual familial aggregation
of OvC was accounted for in this model by a polygenic compo-
nent reﬂecting the additive effects of a large number of genetic
variants. The polygenic component Pi for each individual was
divided into two parts for this purpose: a known-variant poly-
genic component Pk,i reﬂecting the polygenic risk score (PRS)
due to 17 SNPs known to be associated with OvC17 and an
unknown residual polygenic component PU,i. The two compo-
nents were assumed to be independent and normally distributed
with mean 0 and variance s2K and s
2
U, respectively (see details in
online supplementary material; methods). s2K was calculated
using previously described methods,16 based on the known
allele frequencies and per-allele OR estimates. s2U is then
obtained as the difference between the total polygenic variance
and variance of the PRS.
Distribution of OvC risk and implications for OvC prevention
The OvC risk associated with any individual common genetic
variant is very small compared with rare variants like BRCA1.
However, as there are thought to be many as yet undiscovered
common variants and their effects are assumed to be additive
on the logarithmic scale a woman with a high polygenic load is
likely to have a greatly increased risk of OvC compared with
someone with a low polygenic load. Being able to distinguish
between high-risk and low-risk individuals in the population
could be a valuable tool in clinical practice. Therefore, we con-
sidered the potential for risk prediction based both on known
common variants and the total hypothesised polygenotype. We
followed a similar approach to the methods described in
ref. [18] (see online supplementary material for more details).
We calculated the proportions of the population and of cancer
cases at different levels of SNP risk and polygenic risk and
plotted against each other for comparison purposes. This pro-
vides an informative measure of the relationship between risk
distribution in the population and among cancer cases. In the
hypothetical future when an individual’s polygenic risk can be
estimated with a high degree of accuracy, either from family
history or because most of the currently theoretical polygeno-
type is accounted for by known variants, these measures could
be used to estimate what proportions of the population would
need to be monitored/screened/followed in order to detect a
particular percentage of OvCs. This could also potentially con-
tribute to stratifying population by OvC risk to enable targeting
of effective screening/preventive intervention strategies for
appropriate risk groups.
RESULTS
Data from 1548 OvC cases recruited into the SEARCH study
were used for our analyses. Female relatives of probands
included 1340 mothers, 1404 sisters and 1144 daughters, of
whom 80 were also diagnosed with OvC and 191 with breast
cancer. The numbers of probands and their ﬁrst-degree relatives,
the number of OvCs diagnosed in each group and other sample
characteristics are summarised in online supplementary table S1.
All probands were screened for BRCA1 and BRCA2 mutations,
identifying 44 and 62 carriers, respectively. The loci, minor
allele frequencies and ORs of the 17 SNPs used in incorporating
their effects into the ﬁnal model are displayed in online supple-
mentary table S2.
Segregation analyses for OvC incorporating the effects of
BRCA1 and BRCA2 mutations
The results for the seven models that incorporate the explicit
effects of BRCA1 and BRCA2 on OvC risk and that assume
cohort-speciﬁc incidences are summarised in table 1. All the
seven models that accounted for the residual familial aggrega-
tion to OvC (in addition to BRCA1 and BRCA2) provided sig-
niﬁcantly better ﬁt than the model that included only BRCA1
and BRCA2 (p <2.8×10−5). The worst-ﬁtting model for the
residual familial aggregation of OvC, other than BRCA1 and
BRCA2, was the major recessive and the most parsimonious was
the polygenic model, with AICs of 5772.244 and 5764.372,
respectively. Although the mixed models of inheritance all had
slightly larger log-likelihoods, they did not improve the ﬁt sig-
niﬁcantly over the model with only a polygenic component in
addition to the BRCA1 and BRCA2 effects (LRT p values
>0.14). In all models that included a hypothetical third major
gene, the relative risk for the susceptible women was very high
(ranging between ∼54 and ∼122). The estimated population
allele frequency for BRCA1 and BRCA2 under the polygenic
model were 0.08% (95% CI 0.06% to 0.11%) and 0.26% (95%
CI 0.002% to 0.33%), respectively, with a SD of the polygenic
component of 1.43 (95% CI 1.1 to 1.86).
Predicted number of BRCA1 and BRCA2 mutation carriers
and family members diagnosed with OvC
The expected numbers of BRCA1 and BRCA2 mutation carriers
computed under each of the models are displayed in table 2. In
line with magnitude of the log-likelihoods, all seven models
gave similar predictions that were noticeably more accurate than
the model that did not allow for additional residual familial
aggregation other than the effects of BRCA1 and BRCA2. The
polygenic model performed best for predicting the number of
BRCA2 mutation carriers and there was a slight improvement in
accuracy of BRCA1 number under the mixed models. In com-
parison, under the current implementation of BOADICEA, the
predicted BRCA1 numbers were very close to the observed
values but the number of BRCA2 carriers was substantially
underpredicted (p value for difference between observed and
expected number of mutations=4.64E-16).
Similarly, when computing the expected number of families
with a mother, a sister or mother and sister diagnosed with
OvC, the predicted numbers were closer to that observed for
the polygenic and mixed models of inheritance (see online sup-
plementary table S3).
Predicting future OvC risks
We estimated the probabilities of developing OvC for a
50-year-old woman born in 1940, with the following family his-
tories: (i) no information on relatives; (ii) having a mother and
sister cancer free at ages 65 and 50; (iii) mother and sister diag-
nosed with OvC at ages 65 and 50; and (iv) and (v) with both
combinations of one diagnosed and one cancer free at these
same ages. We compared these estimates with the risk estimates
from the current version of BOADICEA.
Figure 1 displays the probabilities of developing OvC for a
50-year old woman without a BRCA1 or BRCA2 mutation.
Under the best-ﬁtting model, the risk of OvC increases with
increasing number of relatives diagnosed with OvC. In contrast,
the corresponding predictions under BOADICEA remain the
same under all assumptions about family history. Similar pat-
terns are observed when the index female is assumed to carry a
BRCA1, or a BRCA2 mutation, where the risks in mutation
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carriers also depend on the exact family history information
(see online supplementary ﬁgures S1 and S2). Under
BOADICEA, the risks in mutation carriers are not modiﬁed by
family history and are all very close to the corresponding risks
predicted by our polygenic model algorithm for a women with
no family history information.
Incorporating common alleles into the model
The loci, minor allele frequencies and ORs for the 17 SNPs con-
sidered are displayed in online supplementary table S2. Under
the assumptions that the effects of the SNPs on OvC are all
mutually independent and the same for BRCA1 carriers, BRCA2
carriers and non-carriers, each observed SNP proﬁle was trans-
lated into a PRS. This PRS was assumed to have a centralised
normal distribution with a variance of 0.0915, explaining about
4.5% of the total polygenic variance in our model.
The lifetime risks of OvC to a 20-year-old non-BRCA1/2
mutation carrier, conditional on known PRS and family history
of OvC, are shown in ﬁgure 2. As expected, the lifetime risk of
developing OvC rose exponentially with increasing PRS. For
example, the lifetime risk of OvC for a woman without a
BRCA1 or BRCA2 mutation but with two affected ﬁrst-degree
relatives is predicted to be >5% if she is at the top 50% of the
PRS distribution.
Examples of age-speciﬁc risks for a 50-year-old woman at the
5th and 95th percentiles of the PRS and by different family
history assumptions are shown in online supplementary ﬁgures
S3–S5
Implications of the polygenic model for OvC prevention
For a polygenic log-risk with the SD of 1.434, estimated under
the best-ﬁtting segregation analysis model, and assuming a base-
line population OvC risk of 0.02 by age 80, the half of the
population at higher risk accounts for 92% of all OvCs.
Figure 3 displays the proportion of the population that have a
risk greater than a given level and the proportion of the cases
predicted to occur within this subgroup. From these curves, it
can be seen that 50% of all cancers occur in the 7.7% of the
population with a risk of 5.6% or more.
In ﬁgure 4, the population proportions are plotted against the
case proportions accounted for, for the polygenic log-risk distri-
butions and the combined SNP-effect distributions. The total
known variance of the effects of 17 known SNPs is
s2K ¼ 0:0915 (see online supplementary material and methods).
Due to the low known variance, the distinction between popula-
tion and case risk is very low for the 17 SNPs alone.
DISCUSSION
We used complex segregation analysis to develop a risk-
prediction model for familial OvC that incorporates the effects
of BRCA1 and BRCA2 mutations, family history and several
newly established common OvC susceptibility alleles using data
from a population-based study of OvC cases in the UK. Our
model accounts for the familial aggregation of OvC and helps
inform a major unresolved clinical question on how to counsel
women with family history of OvC but without BRCA1 or
BRCA2 mutations.
The most parsimonious model included the effects of BRCA1
and BRCA2 mutations together with a polygenic component.
This suggests that most of the familial aggregation not
accounted for by BRCA1 and BRCA2 consists of the effects of a
large number of genetic variants, each having small contribu-
tions to the OvC familial risk. This is in line with results from
recent OvC GWAS19–22 that have demonstrated that common
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low-risk OvC susceptibility alleles exist. Parallel studies in breast
cancer suggested that thousands of such genetic susceptibility
alleles are likely to exist, which explain a substantial fraction of
the unexplained genetic variability.23 A similar model is likely to
apply to OvC. A model that included an additional, dominantly
inherited, high-penetrance gene had the highest likelihood. Such
a model could reﬂect the joint effects of other rare OvC suscep-
tibility variants that confer higher risks collectively. However,
our analysis may be underpowered as this model did not ﬁt sig-
niﬁcantly better than the polygenic model.
Previous OvC segregation analyses24 25 that accounted for
BRCA1 and BRCA2 mutations were based on 10-fold smaller
sample set of high-risk OvC families and did not investigate
polygenic models for the residual familial aggregation of OvC.
In contrast to the present study, those studies found no signiﬁ-
cant evidence of a third high-penetrance gene in addition to
BRCA1 and BRCA2. The difference could be explained primarily
by the much lower power of those analyses due the smaller
sample size but also due to the fact the ascertainment adjust-
ment involved conditioning on all family phenotypes that
imposed a much greater penalty in comparison to the present
analysis that used families selected only on the OvC status of
the index case.
Under the best-ﬁtting model, the BRCA1 and BRCA2 muta-
tion frequencies were estimated to be 0.00079 and 0.0026,
respectively, corresponding to a carrier frequency of 1 in 630
population for BRCA1 and 1 in 195 population for BRCA2.
These were higher than the BOADICEA estimates of 0.0006 for
BRCA1 and 0.001 for BRCA2,10 but the difference was signiﬁ-
cant only for BRCA2 (p values 0.13 and 0.00002). This was
also reﬂected in the signiﬁcant underprediction of BRCA2 muta-
tions under the BOADICEA model in the current dataset. This
Table 2 Number of mutation carriers predicted by each model and comparison with observed numbers
Model for the residual
familial aggregation
Observed BRCA1
carriers
Expected BRCA1
carriers
Observed BRCA2
carriers
Expected BRCA2
carriers χ2 value*
Baseline 44 56.95 62 63.59 2.98
Polygenic 44 49.32 62 61.98 0.57
Dominant major 44 55.62 62 63.08 2.45
Recessive major 44 55.97 62 63.11 2.58
General major 44 55.62 62 63.08 2.45
Dominant mixed 44 48.07 62 61.01 0.36
Recessive mixed 44 49.08 62 61.10 0.54
General mixed 44 48.05 62 61.02 0.36
BOADICEA 44 45.76 62 23.03 66.01
*χ2 value, value of χ2 goodness-of-fit test.
BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrrier Estimation Algorithm.
Figure 1 Predicted risks of ovarian cancer over time to a woman born in the 1940 birth cohort without a BRCA1 or BRCA2 mutation by family
history. The predicted ovarian cancer risks under the most parsimonious model vary by extent of family history of ovarian cancer. In contrast, under
the Breast and Ovarian Analysis of Disease Incidence and Carrrier Estimation Algorithm the predicted ovarian cancer risks remain the same under all
scenarios.
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Figure 2 Lifetime risks of ovarian cancer to a 20-year-old born in the 1940 birth cohort without a BRCA1 or BRCA2 mutation with different
polygenic risk score (PRS) and family history. Graph of the change in probabilities of developing ovarian cancer by age 80 as PRS increases from
−0.8 to 0.8, to a 20 year old with ﬁve different family histories. The two dotted lines, at −0.496 and 0.496, indicate the PRS of those at the 5th
and 95th percentile of risk.
Figure 3 Proportion of population above a speciﬁed absolute risk of ovarian cancer and proportion of cases occurring in that fraction of the
population. Half the population have an absolute risk of ovarian cancer greater than 0.72% by age 80 and 92% of all cases occur in this half of the
population. Half of all cancers occur in the 7.7% of the population with risk higher than 5.6%.
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difference between the studies is probably partly due to the data
sources and differences in the mutation screening techniques.
The 2785 families used to ﬁt the BOADICEA algorithm were
ascertained primarily through population-based patients with
breast cancer. This source of difference would be in line with
the fact that BOADICEA was found to predict BRCA1 and
BRCA2 mutations and breast cancer risk well in independent
datasets of families with breast cancer.10 26–28 BOADICEA has
not been evaluated so far in families ascertained on the basis of
OvC only. Another possible factor is the mutation screening
methods. The current study is based on currently available
sequencing technologies6 that are estimated to be more sensitive
in detecting mutations than the techniques used in the late
1990s.29 Moreover, the knowledge of which mutations are actu-
ally pathogenic has improved substantially over time.30 Both of
these factors could contribute to higher mutation frequencies,
although it is unclear why the difference is only signiﬁcant for
BRCA2. An alternative explanation could be a differential
response rate for participating in the present study between
mutation carriers and non-carriers. BRCA1 and BRCA2 muta-
tions have both been associated with improved short-term OvC
survival. In particular, BRCA2 mutation carriers have been
reported to have a better prognosis.31 32 If women with short
prognosis are more likely to participate in the study, this could
potentially lead to an overestimation of the mutation frequency.
However, data on response differences by prognostic character-
istics are not available to assess this.
In the long term, we expect that these differences will be
resolved by ﬁtting a single algorithm to all available data that
models comprehensively both the genetic susceptibility to breast
cancer and OvC. However, at this stage this is not feasible based
on current technologies due to computational complexities
(in particular, the number of underlying genotypes in the
models). The current approach aims to develop separate algo-
rithms for the susceptibility to breast cancer and OvC that indi-
vidually incorporate the explicit effects of all observed and
unobserved genetic variants such that we obtain accurate risks
of each cancer. Validation studies in independent datasets will
determine the most appropriate model for use in each context.
As technologies evolve over time, in the long term we expect to
synthesise the models into a single algorithm.
In our analyses, we took account of OvCs occurring after a
breast cancer diagnosis, assuming the OvC incidence remains
the same before and after the breast cancer diagnosis. Repeating
the analysis but censoring at the ﬁrst cancer yielded similar
results (eg, under the polygenic model BRCA1 mutation fre-
quency was estimated to be 0.083% and BRCA2 mutation fre-
quency was 0.27% with a polygenic SD of 1.46). Therefore,
our results were not sensitive to these assumptions.
In our analysis, we aimed to include only epithelial OvCs.
However, subsequent to the model ﬁtting process, additional
pathology information became available, which revealed 41 of
the probands’ tumours to be non-epithelial OvCs. This con-
sisted of one BRCA2 carrier and 40 non-carriers, were
non-epithelial OvCs. Reﬁtting the models using only epithelial
OvCs had very little effect on results. Under the polygenic
model, the estimated BRCA1 and BRCA2 mutation frequencies
were 0.081% and 0.26%, polygenic SD was 1.44 and the esti-
mated numbers of BRCA1 and BRCA2 carriers were 48.6 and
60.8, respectively.
Our models assumed that the mutation testing sensitivities
were 0.9 for both BRCA1 and BRCA2. Obtaining exact estimates
is difﬁcult, but in practice mutation sensitivities could be lower.
We reﬁtted the models using a sensitivity parameter of 0.83 for
Figure 4 Proportion of cases accounted for by a given proportion of the population above a speciﬁed risk of ovarian cancer according to the total
polygenic risk and the observed 17 SNP distribution. Under the total polygenic risk distribution, 50% of cancers occur in the 7.7% of the population
at highest risk and 92.4% of cancers occur in the half of the population at greater-than-average risk, whereas under the 17 SNP only 62% of
cancers occur in the 50% at higher risk and 50% of cases are spread among almost 40% of the population at highest risk.
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BRCA1 and 0.76 for BRCA2.6 Under the polygenic model, the
estimated BRCA1 and BRCA2 mutation frequencies were slightly
higher at 0.086% and 0.3%, respectively, and the polygenic SD
decreased slightly to 1.375, but none of these were signiﬁcantly
different than the results under a sensitivity of 0.9. These pat-
terns are expected as the mutation frequency and mutation
screening sensitivity parameters are confounded.
One possible source of bias in our analysis is the possibility of
errors in the reporting of family cancer history. However, previ-
ous studies have found reported OvC history in ﬁrst-degree rela-
tives to be reasonably accurate (83.3% probability of agreement
between reported OvC status in ﬁrst-degree relatives and estab-
lished status).33 34 Therefore, the fact that the OvC diagnoses in
relatives are not conﬁrmed is unlikely to have a great impact on
our results. Another possible weakness of our study is the usage
of external estimates of breast cancer and OvC relative risks to
BRCA1 and BRCA2 mutation carriers. However, due to the
small number of mutation carriers in the SEARCH dataset, it
was not possible to estimate reliably the cancer risks for BRCA1
and BRCA2 mutation carriers. The estimates used were based
on some of the largest studies available.10 35 Future studies
should aim to analyse all the data jointly.
Under our models, the probabilities of developing OvC
increase with the number of OvCs in relatives, while under
BOADICEA10 the risks remain invariable, at values very close to
those we predicted for someone with no recorded family
history, which for non-BRCA1 or non-BRCA2 carriers is close
to the population risk. This is due to the fact that BOADICEA,
along with other previously developed algorithms such as
BRCAPRO,3 uses only BRCA1 and BRCA2 mutations to model
genetic susceptibility to OvC. As a result, under BOADICEA
and BRCAPRO, OvC risks are determined only by the BRCA1
and BRCA2 mutation status, no matter what their family history
is. Three quarters of OvC familial relative risk is not accounted
for by BRCA1 and BRCA2 mutations;1 therefore, the present
models are more realistic. As it stands, BOADICEA and
BRCAPRO could underestimate the risk to many individuals
with a family history of OvC but no identiﬁed mutations.
In all models incorporating a polygenic component or known
SNPs, the effects were assumed to be the same for carriers of a
BRCA1 or BRCA2 mutation and non-carriers. This assumption
is supported by recent studies17 36 37 where all but one of the
OvC loci identiﬁed through GWAS were found to be associated
with risk to a similar relative extent in BRCA1 and BRCA2 car-
riers and non-carriers.38 If future studies identify additional
BRCA1-speciﬁc or BRCA2-speciﬁc modiﬁers of risk, it should be
possible to extend the present model to allow for this level of
complexity.
Although we have incorporated the explicit effects of the
common low-risk alleles, future efforts should focus on incorp-
orating the explicit effects of other intermediate risk OvC sus-
ceptibility variants such as RAD51C, RAD51D and BRIP1.39–41
However, prior to incorporating those into risk prediction
models, it is critical to obtain precise estimates of the risks con-
ferred by such mutations that currently are not available.
We also used our models to investigate the possible implica-
tions for OvC risk stratiﬁcation in the population. Using the
parameters from the polygenic model, we estimate that 50% of
OvCs occur within 7.7% of the population at highest risk.
Meanwhile, half of the population at lower risk is forecast to
contain only 1 in 13 cancer cases. Targeting the 10% at highest
polygenic risk for preventative measures or excluding the
low-risk half could therefore lead to a much more efﬁcient dis-
tribution of resources. However, to achieve this will require that
we identify all the genetic factors that contribute to polygenic
inheritance. The almost ﬂat curve in ﬁgure 4 from the SNP
log-risk distribution, with 50% of the population at higher risk
predicted to contain around only 60% of cases, suggests very
low power to discriminate between high-risk and low-risk indi-
viduals on SNP proﬁles alone. It is perhaps not surprising as
currently only 4.5% of the OvC polygenic variance is accounted
for by known low-penetrance genetic variants. However, the
currently known SNP proﬁles in combination with family
history information and other risk factors for the disease are
expected to have a greater impact for individualised OvC risk
prediction, as demonstrated by our model.
Our model can be used in the genetic counselling process of
women with family history of OvC as well as for counselling
women both with and without BRCA1 or BRCA2 mutations.
This would be helpful to both BRCA1 and BRCA2 carriers and
non-carriers while making decisions regarding clinical interven-
tions following counselling. Probabilities of developing OvC
based on family history, BRCA1, BRCA2 mutation status and/or
polygenic risk could be used to assess the risk to an individual
and to discriminate between high-risk and low-risk individuals,
which may in time prove useful for targeting appropriate
interventions.
FUTURE RESEARCH
Although the mutation carrier probability algorithms produced
very accurate estimates of the number of carriers in the
SEARCH data, an external validation is needed to establish the
performance of the model in independent datasets and to assess
the model performance in predicting OvC risk in prospective
studies. Future plans to extend the models include the addition
of lifestyle and reproductive factors such as parity, breast
feeding and oral contraceptive use,42 mutations in genes such as
RAD51C, RAD51D and BRIP1 that are known to be associated
with OvC risk,39–41 competing causes of mortality and differ-
ences in the associations of the various risk factors with differ-
ent OvC morphological subtypes. The ultimate goal is to
combine the models within the BOADICEA framework and
develop a comprehensive breast and ovarian risk user-friendly
prediction tool.
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